{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-073419","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2026-06-12T20:05:21+00:00","discovered_at":"2026-06-12T20:07:00.305987+00:00","generated_at":"2026-06-12T20:10:48.881258+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Nuvectis Pharma annual meeting elects director; proxy share count corrected","bullets":["Proxy mistakenly stated 27,668,036 shares outstanding; correct count is 26,614,628.","Quorum of 60.8% (16,193,686 shares) present at June 11, 2026 annual meeting.","Ron Bentsur elected Class I director with 8,354,838 votes for, 391,265 against.","Kesselman & Kesselman ratified as independent auditor for FY2026 (15,662,222 for)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-073419","json":"https://secwatch.observer/filing/0001104659-26-073419.json","markdown":"https://secwatch.observer/filing/0001104659-26-073419.md","text":"https://secwatch.observer/filing/0001104659-26-073419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926073419/0001104659-26-073419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926073419/tm2617533d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T20:10:48.881258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2671033513cc987424a068c869652e0b8c411d6a","claim":"Nuvectis Pharma, Inc. shareholders approved Election of Class I director to hold office until the 2029 annual meeting at the 2026-06-11 meeting.","evidence_excerpt":"The vote with respect to the election of the Class I director to hold office until the 2029 annual meeting was as follows: Director Votes For Votes Against Abstentions / Votes Withheld Broker Non-Votes Ron Bentsur 8,354,838 391,265 216 7,447,367","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926073419/0001104659-26-073419-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"},{"claim_id":"5a9a5e639a4175e018e21defde37793e22c69671","claim":"Nuvectis Pharma, Inc. shareholders approved Ratification of Kesselman & Kesselman as independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting.","evidence_excerpt":"The vote with respect to the ratification of Kesselman & Kesselman as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was as follows: Votes For Votes Against Abstentions / Votes Withheld Broker Non-Votes 15,662,222 10,574 520,890 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926073419/0001104659-26-073419-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-11"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}